143 related articles for article (PubMed ID: 22447507)
1. The perils of pharmacological treatment for obesity: a case of sibutramine-associated cardiomyopathy and malignant arrhythmias.
Schamroth CL
Cardiovasc J Afr; 2012 Mar; 23(2):e11-2. PubMed ID: 22447507
[TBL] [Abstract][Full Text] [Related]
2. Withdrawal of sibutramine for weight loss: where does this leave clinicians?
Czernichow S; Batty GD
Obes Facts; 2010 Jun; 3(3):155-6. PubMed ID: 20616603
[No Abstract] [Full Text] [Related]
3. [Questions surrounding sibutramine for obesity].
Nau JY
Rev Med Suisse; 2010 Jan; 6(231):76. PubMed ID: 20196440
[No Abstract] [Full Text] [Related]
4. Controversy about the cardiovascular safety of sibutramine.
Scheen AJ
Drug Saf; 2010 Jul; 33(7):615-8. PubMed ID: 20553062
[No Abstract] [Full Text] [Related]
5. Severe symptomatic hyponatremia during sibutramine therapy: a case report.
Esposito P; Rampino T; Gregorini M; Soccio G; Piotti G; Bedino G; Balenzano CT; Roscini E; Cosmai L; Portalupi V; Libetta C; Dal Canton A
Am J Kidney Dis; 2008 Jul; 52(1):137-9. PubMed ID: 18487000
[TBL] [Abstract][Full Text] [Related]
6. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders.
McElroy SL; Frye MA; Altshuler LL; Suppes T; Hellemann G; Black D; Mintz J; Kupka R; Nolen W; Leverich GS; Denicoff KD; Post RM; Keck PE
Bipolar Disord; 2007 Jun; 9(4):426-34. PubMed ID: 17547588
[TBL] [Abstract][Full Text] [Related]
7. Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study.
Ersoz HO; Ukinc K; Baykan M; Erem C; Durmus I; Hacihasanoglu A; Telatar M
Int J Obes Relat Metab Disord; 2004 Mar; 28(3):378-83. PubMed ID: 14724665
[TBL] [Abstract][Full Text] [Related]
8. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias.
Wooltorton E
CMAJ; 2002 May; 166(10):1307-8. PubMed ID: 12041851
[No Abstract] [Full Text] [Related]
9. [Observational study. Sibutramine in general practice].
MMW Fortschr Med; 2001 Apr; 143(15):43. PubMed ID: 11349321
[No Abstract] [Full Text] [Related]
10. [Pharmacotherapy in the treatment of obesity].
Hamann A
MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
[TBL] [Abstract][Full Text] [Related]
11. A comparison of sibutramine and dexfenfluramine in the treatment of obesity.
Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
Obes Res; 1998 Jul; 6(4):285-91. PubMed ID: 9688105
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
Int J Obes Relat Metab Disord; 1998 Jan; 22(1):32-8. PubMed ID: 9481597
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women.
Sari R; Eray E; Ozdem S; Akbas H; Coban E
Clin Exp Med; 2010 Sep; 10(3):179-84. PubMed ID: 19937362
[TBL] [Abstract][Full Text] [Related]
14. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
Hauner H; Meier M; Wendland G; Kurscheid T; Lauterbach K; ;
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325
[TBL] [Abstract][Full Text] [Related]
15. Sibutramine-associated QT interval prolongation and cardiac arrest.
Ernest D; Gershenzon A; Corallo CE; Nagappan R
Ann Pharmacother; 2008 Oct; 42(10):1514-7. PubMed ID: 18728104
[TBL] [Abstract][Full Text] [Related]
16. A 'natural' weight loss product containing sibutramine.
van Hunsel F; Venhuis BJ; Keizers PH; Kant A
Drug Test Anal; 2016; 8(3-4):311-4. PubMed ID: 27072843
[No Abstract] [Full Text] [Related]
17. Sibutramine produces dose-related weight loss.
Bray GA; Blackburn GL; Ferguson JM; Greenway FL; Jain AK; Mendel CM; Mendels J; Ryan DH; Schwartz SL; Scheinbaum ML; Seaton TB
Obes Res; 1999 Mar; 7(2):189-98. PubMed ID: 10102256
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
Maggioni AP; Caterson I; Coutinho W; Finer N; Gaal LV; Sharma AM; Torp-Pedersen C; Bacher P; Shepherd G; Sun R; James P;
J Cardiovasc Pharmacol; 2008 Nov; 52(5):393-402. PubMed ID: 19033818
[TBL] [Abstract][Full Text] [Related]
19. Sibutramine use associated with reversible hepatotoxicity.
Chounta A; Tsiodras S; Zouridakis S; Doumas M; Giamarellou H
Ann Intern Med; 2005 Nov; 143(10):763-4. PubMed ID: 16287809
[No Abstract] [Full Text] [Related]
20. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
